Skip to main content
Tetra Bio-Pharma Inc. logo

Tetra Bio-Pharma Inc. — Investor Relations & Filings

Ticker · TBPMQ ISIN · CA88166Y1007 LEI · 5299000CYH3P8XC2UO53 TSX Manufacturing
Open in API
Filings indexed 720 across all filing types
Latest filing 2020-07-23 Regulatory Filings
Country CA Canada
Listing TSX TBPMQ

About Tetra Bio-Pharma Inc.

https://tetrabiosciences.com/

Tetra Bio-Pharma is a biopharmaceutical company specializing in the discovery and development of cannabinoid-derived drugs and medicinal plant-based products. The company maintains an advanced pipeline encompassing biopharmaceuticals, natural health, and veterinary products. Clinical programs are focused on therapeutic areas such as inflammation, pain management (including alternatives to opioids), and ophthalmology. Tetra emphasizes rigorous clinical trials and scientific evidence, utilizing novel approaches, unique mechanisms of action, and high-quality delivery methods to address unmet patient needs.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2020-07-23 English
52-109FV2 - Certification of interim filings - CEO (E).pdf
Regulatory Filings
2020-07-21 English
Interim MD&A - English.pdf
Regulatory Filings
2020-07-21 English
Interim financial statements/report – English.pdf
Regulatory Filings
2020-07-21 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing positive feedback from the FDA on a Pre-Investigational New Drug (PIND) application for a drug candidate ARDS-003 to be studied in COVID-19 patients. It discusses regulatory feedback, clinical trial plans, and drug development progress. There are no financial statements, earnings data, or detailed management analysis. The document is not a report itself but an announcement of regulatory progress and clinical development updates. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a call transcript or a shareholder meeting document. The content is primarily a regulatory and clinical development update. Given the nature of the document as a regulatory announcement and company update on drug development status, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other categories.
2020-07-16 English
News release - English.pdf
Capital/Financing Update Classification · 95% confidence The document is a press release announcing that Tetra Bio-Pharma has received conditional approval to graduate from the TSX Venture Exchange to the Toronto Stock Exchange (TSX). It discusses the listing process, conditions, and future plans for trading shares and warrants on the TSX. There is no financial data, no detailed report, no regulatory filing, or certification. The content is an update on the company's capital market status and listing progress, which fits the category of Capital/Financing Update (CAP). The document length is about 6000 characters, which is consistent with a detailed announcement but not a full financial report. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-07-15 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.